Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes.

Tanaka K, Saisho Y, Kawai T, Tanaka M, Meguro S, Irie J, Imai T, Shigihara T, Morimoto J, Yajima K, Atsumi Y, Takei I, Itoh H

Endocrine journal26 Feb 2015Cited by 23 (Europe PMC)

PMID25739726DOI10.1507/endocrj.ej14-0602PepBankPUB-25739726

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight or obese Japanese adults with type 2 diabetes, HbA1c reduction at week 24 with liraglutide was comparable to metformin.
In plain wordsIn overweight or obese Japanese adults with type 2 diabetes, liraglutide lowered HbA1c about as much as metformin.
Peptide
Liraglutide
Outcome
No significant changeHbA1c reduction at week 24
Study
n = 46
Comparator
Metformin
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
HbA1c reduction
−0.8%
liraglutide (n = 22)
HbA1c reduction
−0.95%
metformin (n = 24)
Source sentences
Summary
Reduction in HbA1c at week 24 was comparable between the metformin (n = 24) and liraglutide (n = 22) groups (-0.95 ± 0.80% vs. -0.80 ± 0.88%, p = 0.77)
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a 24-week, open-labeled, randomized controlled study.
Summary · context
Overweight or obese patients with T2DM aged 20-75 years with suboptimal glycemic control were randomized to liraglutide or metformin monotherapy.
Summary · context
A total of 46 subjects completed the study, and analysis was conducted in this cohort.
Report a problemFND-2573972601
02HumanRandomized controlled trialEfficacy outcome
In overweight or obese Japanese adults with type 2 diabetes, weight gain did not differ significantly between liraglutide and metformin.
In plain wordsIn overweight or obese Japanese adults with type 2 diabetes, weight gain was not significantly different between liraglutide and metformin.
Peptide
Liraglutide
Outcome
No significant changeWeight gain
Study
n = 46
Comparator
Metformin
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
There was no significant difference in weight gain or incidence of hypoglycemia between the groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a 24-week, open-labeled, randomized controlled study.
Summary · context
Overweight or obese patients with T2DM aged 20-75 years with suboptimal glycemic control were randomized to liraglutide or metformin monotherapy.
Summary · context
A total of 46 subjects completed the study, and analysis was conducted in this cohort.
Report a problemFND-2573972603
03HumanRandomized controlled trialSafety outcome
In overweight or obese Japanese adults with type 2 diabetes, the incidence of hypoglycemia did not differ significantly between liraglutide and metformin.
In plain wordsIn overweight or obese Japanese adults with type 2 diabetes, low blood sugar events were not significantly different between liraglutide and metformin.
Peptide
Liraglutide
Outcome
No significant changeIncidence of hypoglycemia
Study
n = 46
Comparator
Metformin
Analysis
Secondary
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
There was no significant difference in weight gain or incidence of hypoglycemia between the groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a 24-week, open-labeled, randomized controlled study.
Summary · context
Overweight or obese patients with T2DM aged 20-75 years with suboptimal glycemic control were randomized to liraglutide or metformin monotherapy.
Summary · context
A total of 46 subjects completed the study, and analysis was conducted in this cohort.
Report a problemFND-2573972604
04HumanRandomized controlled trialSafety outcome
In overweight or obese Japanese adults with type 2 diabetes, diarrhea was less frequent with liraglutide than with metformin.
In plain wordsIn overweight or obese Japanese adults with type 2 diabetes, diarrhea was less frequent with liraglutide than with metformin.
Peptide
Liraglutide
Outcome
DecreaseDiarrhea
Study
n = 46
Comparator
Metformin
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Diarrhea was more frequent in the metformin group, while constipation was more frequent in the liraglutide group.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a 24-week, open-labeled, randomized controlled study.
Summary · context
Overweight or obese patients with T2DM aged 20-75 years with suboptimal glycemic control were randomized to liraglutide or metformin monotherapy.
Summary · context
A total of 46 subjects completed the study, and analysis was conducted in this cohort.
Report a problemFND-2573972605
05HumanRandomized controlled trialSafety outcome
In overweight or obese Japanese adults with type 2 diabetes, constipation was more frequent with liraglutide than with metformin.
In plain wordsIn overweight or obese Japanese adults with type 2 diabetes, constipation was more frequent with liraglutide than with metformin.
Peptide
Liraglutide
Outcome
IncreaseConstipation
Study
n = 46
Comparator
Metformin
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
constipation was more frequent in the liraglutide group.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a 24-week, open-labeled, randomized controlled study.
Summary · context
Overweight or obese patients with T2DM aged 20-75 years with suboptimal glycemic control were randomized to liraglutide or metformin monotherapy.
Summary · context
A total of 46 subjects completed the study, and analysis was conducted in this cohort.
Report a problemFND-2573972606
06HumanRandomized controlled trialEfficacy outcome
In overweight or obese Japanese adults with type 2 diabetes, the liraglutide group reached its maximal HbA1c reduction more rapidly than the metformin group.
In plain wordsIn overweight or obese Japanese adults with type 2 diabetes, the greatest HbA1c drop came sooner with liraglutide than with metformin.
Peptide
Liraglutide
Outcome
Not applicableSpeed of maximal HbA1c reduction
Study
n = 46
Comparator
Metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
while the liraglutide group reached maximal reduction more rapidly than did the metformin group.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a 24-week, open-labeled, randomized controlled study.
Summary · context
Overweight or obese patients with T2DM aged 20-75 years with suboptimal glycemic control were randomized to liraglutide or metformin monotherapy.
Summary · context
A total of 46 subjects completed the study, and analysis was conducted in this cohort.
Report a problemFND-2573972602
07HumanRandomized controlled trialEfficacy outcome
In overweight or obese Japanese adults with type 2 diabetes, treatment satisfaction did not differ significantly between liraglutide and metformin.
In plain wordsIn overweight or obese Japanese adults with type 2 diabetes, treatment satisfaction was not significantly different between liraglutide and metformin.
Peptide
Liraglutide
Outcome
No significant changeTreatment satisfaction
Study
n = 46
Comparator
Metformin
Outcome group
Patient-reported outcomes · Whole body
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
There was no significant difference in treatment satisfaction between the groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a 24-week, open-labeled, randomized controlled study.
Summary · context
Overweight or obese patients with T2DM aged 20-75 years with suboptimal glycemic control were randomized to liraglutide or metformin monotherapy.
Summary · context
A total of 46 subjects completed the study, and analysis was conducted in this cohort.
Report a problemFND-2573972607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.